Coamorphous Lurasidone Hydrochloride–Saccharin with Charge-Assisted Hydrogen Bonding Interaction Shows Improved Physical Stability and Enhanced Dissolution with pH-Independent Solubility Behavior
Source abstract
Abstract
Recently, coamorphous systems, composed of a drug and a guest molecule, have gained increasing interest, due to their ability to overcome limitations associated with amorphous drug alone. In this study, a single-phase coamorphous form of lurasidone hydrochloride (LH) (a water-insoluble atypical antipsychotic agent with pH-dependent solubility) with saccharin (SAC) in a 1:1 molar ratio was obtained and characterized by differential scanning calorimetry and powder X-ray diffraction. Peak shifts in the Fourier transform infrared spectra indicated the formation of charge-assisted hydrogen bonds between the N + -H group of LH and the C═O group of SAC. In comparison to crystalline LH, amorphous LH showed similar solubility and temporary improvement in the intrinsic dissolution rate and supersaturated dissolution, while coamorphous LH-SAC exhibited greatly improved solubility with pH-independent solubility behavior in a pH range of 2–5.5, as well as a persistent enhanced intrinsic dissolution rate and supersaturated dissolution. In addition, coamorphous LH-SAC showed superior physical stability compared to amorphous LH under the long-term storage condition. The coamorphization effect and charge-assisted hydrogen bond in coamorphous LH-SAC were speculated to be responsible for the above phenomena by prohibiting the recrystallization of LH.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Crystallization and Solubility Studies · Crystallography and molecular interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Traditional Chinese Medicine and ‡School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P.R. China
Funding
Ministry of Education of the People's Republic of China · Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions
References (50)
Show source-provided references
1. van Hoogevest P. · Expert Opin. Drug Delivery · 2011 · 8 · 148110.1517/17425247.2011.614228 ↗
2. Sun Y. · AAPS J. · 2012 · 14 · 38010.1208/s12248-012-9345-6 ↗
3. Kaushal A. M. · Crit. Rev. Ther. Drug Carrier Syst. · 2004 · 21 · 13310.1615/CritRevTherDrugCarrierSyst.v21.i3.10 ↗
4. Forster A. · J. Pharm. Pharmacol. · 2001 · 53 · 30310.1211/0022357011775532 ↗
5. Alonzo D. E. · Pharm. Res. · 2010 · 27 · 60810.1007/s11095-009-0021-1 ↗
6. Gupta P. · Pharm. Res. · 2004 · 21 · 176210.1023/B:PHAM.0000045226.42859.b8 ↗
7. Serajuddin A. T. · J. Pharm. Sci. · 1999 · 88 · 105810.1021/js980403l ↗
8. Vasconcelos T. · Drug Discovery Today · 2007 · 12 · 106810.1016/j.drudis.2007.09.005 ↗
9. Lobmann K. · Mol. Pharmaceutics · 2011 · 8 · 191910.1021/mp2002973 ↗
10. Chieng N. · Eur. J. Pharm. Biopharm. · 2009 · 71 · 4710.1016/j.ejpb.2008.06.022 ↗
11. Yamamura S. · Eur. J. Pharm. Biopharm. · 2000 · 49 · 25910.1016/S0939-6411(00)00060-6 ↗
12. Lobmann K. · Eur. J. Pharm. Biopharm. · 2012 · 81 · 15910.1016/j.ejpb.2012.02.004 ↗
13. Nakajima M. · Drug Metab. Dispos. · 1998 · 26 · 261
14. Gagniere E. · Cryst. Growth Des. · 2009 · 9 · 337610.1021/cg801019d ↗
15. Gao Y. · Int. J. Pharm. · 2013 · 450 · 29010.1016/j.ijpharm.2013.04.032 ↗
16. Nasrallah H. A. · J. Psychiatr. Res. · 2013 · 47 · 67010.1016/j.jpsychires.2013.01.020 ↗
17. Ankit M. · Int. J. Res. Ayurveda Pharm. · 2014 · 5 · 63210.7897/2277-4343.055129 ↗
18. Gagniere E. · J. Cryst. Growth · 2009 · 311 · 268910.1016/j.jcrysgro.2009.02.040 ↗
19. Lee K. R. · Xenobiotica · 2011 · 41 · 110010.3109/00498254.2011.603388 ↗
20. Adhiyaman R. · Int. J. Pharm. · 2006 · 321 · 2710.1016/j.ijpharm.2006.04.021 ↗
21. Taniguchi C. · Expert Opin. Drug Delivery · 2014 · 11 · 50510.1517/17425247.2014.881798 ↗
22. Lubach J. W. · Mol. Pharmaceutics · 2013 · 10 · 399710.1021/mp400283j ↗
23. Zhang H. · Acta Crystallogr. Sect. E · 2012 · 68 · o135710.1107/S1600536812012883 ↗
24. Higuchi W. I. · J. Pharm. Sci. · 1965 · 54 · 140510.1002/jps.2600541003 ↗
25. Zakeri-Milani P. · Eur. J. Pharm. Biopharm. · 2009 · 73 · 10210.1016/j.ejpb.2009.04.015 ↗
26. Pu, X. H.; Sun, J.; Han, J. H.; Lian, H.; Zhang, P.; Yan, Z. T.; He, Z. G.J. Nanopart. Res. 2013, 15.10.1007/s11051-013-2043-1 ↗
27. European Medicines Agency.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002713/WC500164684.pdf(Accessed 10 Apr 2015) .
28. Basavoju S. · Pharm. Res. · 2008 · 25 · 53010.1007/s11095-007-9394-1 ↗
29. Wang H. · Chem. Sci. · 2014 · 5 · 344910.1039/C4SC01036A ↗
30. George S. · J. Young Pharm. · 2012 · 4 · 22010.4103/0975-1483.104365 ↗
31. National Institute of Standards and Technology.http://webbook.nist.gov/cgi/cbook.cgi?ID=C569653&Mask=80(Accessed 20 Jan 2015) .
32. Heinz A. · J. Pharm. Pharmacol. · 2009 · 61 · 97110.1211/jpp.61.08.0001 ↗
33. Lesarri A. · J. Chem. Phys. · 2002 · 116 · 411610.1063/1.1434990 ↗
34. Kramer S. F. · J. Pharm. Sci. · 1972 · 61 · 189610.1002/jps.2600611203 ↗
35. Wang Y. · Eur. J. Pharm. Sci. · 2010 · 39 · 27210.1016/j.ejps.2009.12.011 ↗
36. Po H. N. · J. Chem. Educ. · 2001 · 78 · 149910.1021/ed078p1499 ↗
37. Andronis V. · J. Pharm. Sci. · 1997 · 86 · 34610.1021/js9602711 ↗
38. Kim J. H. · Int. J. Pharm. · 2002 · 236 · 8110.1016/S0378-5173(02)00017-0 ↗
39. Zuckerman, D. M.InStatistical Physics of Biomolecules: An Introduction;Zuckerman, D. M., Ed.CRC Press:Boca Raton, FL, USA, 2010; Chapter 9, pp205–234.10.1201/b18849 ↗
40. Elamin A. A. · Int. J. Pharm. · 1994 · 111 · 15910.1016/0378-5173(94)00132-4 ↗
41. Chawla G. · Eur. J. Pharm. Sci. · 2007 · 32 · 4510.1016/j.ejps.2007.05.111 ↗
42. Savolainen M. · Eur. J. Pharm. Biopharm. · 2009 · 71 · 7110.1016/j.ejpb.2008.06.001 ↗
43. Alleso M. · J. Controlled Release · 2009 · 136 · 4510.1016/j.jconrel.2009.01.027 ↗
44. Maruyama S. · J. Cryst. Growth · 2000 · 212 · 23910.1016/S0022-0248(99)00903-3 ↗
45. Charcosset, C.InMembrane Processes in Biotechnologies and Pharmaceutics;Charcosset, C., Ed.Elsevier:Kidlington, UK, 2012; Chapter 8, pp295–321.10.1016/B978-0-444-56334-7.00008-3 ↗
46. Purvis T. · AAPS PharmSciTech · 2007 · 8 · E5810.1208/pt0803058 ↗
47. Yang W. · Eur. J. Pharm. Biopharm. · 2010 · 75 · 3310.1016/j.ejpb.2010.01.011 ↗
48. Lobmann K. · Int. J. Pharm. · 2013 · 453 · 8010.1016/j.ijpharm.2012.05.016 ↗
49. Yoshioka M. · J. Pharm. Sci. · 1994 · 83 · 170010.1002/jps.2600831211 ↗
50. Hancock B. C. · Pharm. Res. · 1995 · 12 · 79910.1023/A:1016292416526 ↗